Ticagrelor Sulfoxide (Mixture of Diastereomers)
CAS: 1644461-85-7
Ref. TR-T437745
| 25mg | 2,605.00 € | ||
| 2500µg | 379.00 € |
Estimated delivery in United States, on Tuesday 23 Jul 2024
Product Information
Name:
Ticagrelor Sulfoxide (Mixture of Diastereomers)
Controlled Product
Synonyms:
- (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylsulfinyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
Description:
Applications Ticagrelor Sulfoxide is an impurity of ticagrelor (T437700). Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS).
References Matetzky, S., et al.: Circulation, 109, 3171 (2004), Bassand, J., et al.: Eur. Heart J., 28, 1598 (2007), Jakubowski, J., et al.: Cardiovasc. Drug Rev., 25, 357 (2007),
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
TRC
Long term storage:
Notes:
Chemical properties
Molecular weight:
538.57
Formula:
C23H28F2N6O5S
Color/Form:
Neat
InChI:
InChI=1S/C23H28F2N6O5S/c1-2-7-37(35)23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(36-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+,37?/m0/s1
InChI key:
InChIKey=DXFXDCXSENDSIK-LJCGIFJESA-N
SMILES:
CCCS(=O)c1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TR-T437745 Ticagrelor Sulfoxide (Mixture of Diastereomers)
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
